Irhythm Technologies (IRTC)
NASDAQ:IRTC
Want to see IRTC full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.44Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was constructive and predominantly positive: the company delivered strong top-line growth (≈26% YoY), meaningful margin expansion (880 bps adjusted EBITDA improvement and +210 bps gross margin), raised full‑year revenue and EBITDA guidance, and showed progress on product, AI, clinical evidence, and international commercialization. Offsetting items include continued GAAP/adjusted net losses (though improved), seasonally negative Q1 free cash flow, elevated operating and litigation-related costs, and outstanding regulatory and legal uncertainties (FDA warning letter, DOJ CID) plus potential coverage ambiguity from proposed LCD language. On balance, the operational and commercial positives materially outweigh the remaining execution and regulatory risks.Company Guidance
Strong Revenue Growth and Upward Guidance
Revenue of $199.4 million in Q1 2026, up 25.7% year over year; company raised full-year 2026 revenue guidance to $875M–$885M, implying 17%–18% YoY growth. Q2 2026 revenue guide of $218M–$220M.
Material Profitability Improvement
Adjusted EBITDA of $14.1 million (7.1% of revenue) in Q1 2026, representing an 880 basis point improvement year over year; company raised full-year adjusted EBITDA margin guidance to 12%–13% (Q2 guide 11.5%–12.5%).
Gross Margin Expansion
Reported gross margin of 70.9% in Q1 2026, an increase of 210 basis points year over year driven by manufacturing automation, clinical operations efficiencies, and scale benefits.
Large Cash Balance Provides Flexibility
Ended Q1 with $549.6 million in cash, cash equivalents, and marketable securities, supporting investments in product innovation, commercial initiatives, and international expansion.
Broad Clinical Adoption and Evidence Base
Platform supported by over 140 publications and recent presentations (ACC, HRS) demonstrating high diagnostic yield; ongoing head-to-head and real-world studies that reinforce Zio’s superiority and potential downstream cost reduction.
Scale, Integration, and Channel Momentum
Approximately 53% of volume flows through EHR-integrated accounts; more than 75% of top 100 customers are integrated. New-store accounts (open <12 months) accounted for ~64% of year-over-year volume growth; U.S. home enrollment ~23% of volume.
AI and Product Roadmap Progress
Proprietary dataset exceeds 3 billion hours of curated ECG data; next-generation AI algorithm 510(k) submitted and expected approval later this year, projected to reduce technician review time by as much as half and materially improve efficiency and margins. Next-generation MCT reaffirmed for H1 2027 launch.
International and Adjacent Market Traction
U.K. delivered the company's best quarter in history; Japan received a modest supplemental reimbursement update for longer-duration monitoring — viewed as an encouraging early signal while premium reimbursement work continues.
IRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $129.16 | $120.80 | -6.47% |
Feb 19, 2026 | $158.88 | $150.96 | -4.98% |
Oct 30, 2025 | $184.12 | $187.30 | +1.73% |
Jul 31, 2025 | $140.18 | $164.97 | +17.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Irhythm Technologies (IRTC) report earnings?
Irhythm Technologies (IRTC) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Irhythm Technologies (IRTC) earnings time?
Irhythm Technologies (IRTC) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRTC EPS forecast?
IRTC EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.